Jagsonpal Pharmaceuticals Financial Results
- Market cap
- ₹1,522 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹163.62 – ₹306.79
In the Q1 quarter, Jagsonpal Pharmaceuticals reported revenue of ₹122 crore, and net profit of ₹13.7 crore. The operating margin was 19%. Earnings per share were ₹10.10.
Summary
Jagsonpal Pharmaceuticals Limited is showing strong operational fundamentals with healthy volume activity and bullish technical indicators.
AI-generated summary of public data — not investment advice · 9 October 2026
Jagsonpal Pharmaceuticals quarterly results
Consolidated figures, newest quarter first.
| Item | Q1 |
|---|---|
| Revenue | 122 |
| Expenses | 98.91 |
| Operating profit | 22.83 |
| Operating margin % | 19% |
| Other income | 45 |
| Interest | 12 |
| Depreciation | 35 |
| Profit before tax | 18.26 |
| Tax % | 25% |
| Net profit | 13.7 |
| EPS (₹) | 10.10 |
Jagsonpal Pharmaceuticals annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | FY25 |
|---|---|
| Revenue | 533 |
| Expenses | 426 |
| Operating profit | 107 |
| Operating margin % | 20% |
| Other income | 180 |
| Interest | 50 |
| Depreciation | 140 |
| Profit before tax | 83.69 |
| Tax % | 25% |
| Net profit | 62.39 |
| EPS (₹) | 40.40 |
| Dividend payout % | 22% |
Source: Company filings (consolidated), in ₹ crore. Data as of 9 October 2026. How this data is compiled.
Jagsonpal Pharmaceuticals financial results — frequently asked questions
What were Jagsonpal Pharmaceuticals' latest quarterly results?
For the Q1 quarter (consolidated), Jagsonpal Pharmaceuticals reported revenue of ₹122 crore, operating profit of ₹22.83 crore and net profit of ₹13.7 crore, with EPS of ₹10.10.
What is Jagsonpal Pharmaceuticals' annual revenue and net profit?
For the financial year ended FY25, Jagsonpal Pharmaceuticals' revenue was ₹533 crore and net profit ₹62.39 crore.
What is the EPS of Jagsonpal Pharmaceuticals?
Quarterly EPS for Q1 was ₹10.10. Annual EPS for FY25 was ₹40.40.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
Trade Jagsonpal Pharmaceuticals With ATS
Track JAGSNPHARM live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.